Comparison of MDS/sAML Study Group With Matched Control Group of Patients With De Novo AML
| . | Study Group . | Control Group . |
|---|---|---|
| No. of patients | 55 | 110 |
| Age (yr) | ||
| <40 | 28 | 56 |
| ≥40 | 27 | 54 |
| Sex | ||
| Male | 23 | 52 |
| Female | 32 | 58 |
| Year of transplant | ||
| 83-87 | 8 | 16 |
| 88-90 | 20 | 40 |
| 91-94 | 27 | 54 Interval, first CR to transplantation (mo) |
| Median | 4 | 4 |
| Range | 0-20 | 0-13 |
| Alive (%) | 20 (36) | 63 (57) |
| Relapse-free alive (%) | 18 (33) | 58 (53) |
| Relapse (%) | 31 (56) | 37 (34) |
| Dead (%) | 35 (64) | 47 (43) |
| Treatment-related death (%) | 6 (11) | 15 (14) |
| . | Study Group . | Control Group . |
|---|---|---|
| No. of patients | 55 | 110 |
| Age (yr) | ||
| <40 | 28 | 56 |
| ≥40 | 27 | 54 |
| Sex | ||
| Male | 23 | 52 |
| Female | 32 | 58 |
| Year of transplant | ||
| 83-87 | 8 | 16 |
| 88-90 | 20 | 40 |
| 91-94 | 27 | 54 Interval, first CR to transplantation (mo) |
| Median | 4 | 4 |
| Range | 0-20 | 0-13 |
| Alive (%) | 20 (36) | 63 (57) |
| Relapse-free alive (%) | 18 (33) | 58 (53) |
| Relapse (%) | 31 (56) | 37 (34) |
| Dead (%) | 35 (64) | 47 (43) |
| Treatment-related death (%) | 6 (11) | 15 (14) |